Biotechnology & Medicine

Latest Revolutionary Advances in CRISPR and Gene Editing

Gene editing technology, especially the CRISPR-Cas system, has brought an unimaginable revolution to the fields of medicine and biology over the past decade. It is a technology that possesses the ability to cut, modify, or repair DNA with extreme precision. Significant breakthroughs in 2025 and 2026 are bringing this technology from laboratory environments directly to millions of patients. Let us take a detailed look at these key milestones.

Full Control Over Gene Editing: PRINCE and Little Prince

One of the major drawbacks of CRISPR technology has been the difficulty of controlling or stopping its activity once it is introduced into the body (in vivo). Researchers at the Chinese Academy of Sciences have discovered a brilliant solution named PRINCE and Little Prince.

Dual-Level Advanced Control

This system combines two distinct mechanisms to ensure gene editing is turned on only via a specific drug inducer, remaining virtually off in its absence. In this setup, not only is the nuclease protein controlled, but guide RNA expression is also regulated through a separate system.

The outcome of this dual control is that no significant background editing occurs under normal conditions, yet upon drug administration, the system operates with high efficiency within just 24 hours.

Successful Trials in Living Organisms

Researchers tested this technology on two different animal models. In the first experiment, targeting the PCSK9 gene in a mouse model—which regulates cholesterol levels—resulted in a 50% reduction in total and LDL (bad) cholesterol levels after a single treatment.

In the second trial targeting the retinal tissue, results showed that this approach reduced pathological vascular leakage and lesion size while improving retinal function.

A New Way to Target Cancer: Utilizing Cas12a2

The greatest challenge in cancer treatment is selectively destroying cancerous cells while preserving healthy ones. Researchers at Utah State University and the Helmholtz Institute developed a method using CRISPR-Cas12a2 to achieve this exact goal.

How Cas12a2 Functions

While standard Cas9 cuts DNA at a specific site, Cas12a2 operates in a completely different manner. Once its guide RNA attaches to a specific RNA target, it functions like a “sharp blade,” destroying surrounding DNA non-specifically, which leads to complete cell destruction.

Single-Point Mutation Targeting

In mouse trials targeting cancer driven by a single-point mutation, Cas12a2 recognized the specific variation and destroyed only the cancer cells, leaving healthy cells completely unharmed. A single treatment resulted in approximately a 50% reduction in tumor volume.

Fighting Solid Tumors: CRISPR T-Cell Therapy

Treating solid tumors (such as lung, ovarian, or breast cancers) with T-cell therapy has historically been challenging. T-knife Therapeutics has developed a novel CRISPR-edited T-cell therapy named TK-6302 to address this barrier.

Targeting the PRAME Protein

This therapy targets the PRAME protein, which is expressed across multiple solid tumors. It incorporates several engineering features, including a high-affinity receptor, a CD8 co-receptor, and a specialized FAS-based checkpoint converter that enhances T-cell survival within the tumor microenvironment. Phase 1 clinical trials have received approval in Europe.

One-Time Cure for Hereditary Disease: Phase 3 Success

A landmark milestone was achieved when an international team led by Amsterdam UMC successfully completed a Phase 3 clinical trial for an in vivo CRISPR therapy.

Treatment for Hereditary Angioedema

The trial targeted Hereditary Angioedema, a rare genetic disorder causing severe, recurrent swelling. Patients receiving an intravenous infusion of the CRISPR therapy lonvoguran-ziclumeran experienced an 87% reduction in swelling attacks, with 62% remaining completely attack-free.

Follow-up data over four years demonstrated that this single-dose treatment maintained both its efficacy and safety profile over the long term.

High-Performance Novel Nucleases

In comparative studies evaluating treatments for conditions like Sickle Cell Disease (SCD), researchers analyzed HiFi SpCas9, SaCas9, and AsCas12a Ultra. Both SaCas9 and AsCas12a Ultra exhibited superior editing efficiency and significantly fewer off-target effects in stem cells compared to standard options.

Advances in DNA Donor Chemistry

Researchers at KAUST discovered that attaching a chemical molecule named Cy5 to one end of donor DNA (5′Cy5 modification) boosted editing efficiency by up to 2.5 times in stem cells and organoids while enhancing cell survival rates. This technique enabled a 30% successful correction rate for the HBB gene in 3D tissue models.

Base Editing in Human Embryos: A Controversial Step

A team led by Columbia University utilized base editing in human embryos to correct pathogenic variants in the PCSK9 and HBG genes without causing chromosomal breakage. However, challenges like off-target editing and mosaicism remain. This research has sparked renewed global ethical debates, with leading medical bodies advocating for strict regulatory frameworks.